Dataset from A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin

Study D5553C0003 is a 28-week, randomized, double-blind, active-controlled, multicenter,
Phase 3 efficacy and safety study with 24-week and 52-week extension phases of simultaneous
administration of exenatide once weekly (EQW) 2 mg and dapagliflozin 10 mg once daily (QD)
compared to EQW 2 mg alone and dapagliflozin 10 mg QD alone in patients with Type 2 diabetes
who have inadequate glycemic control on metformin.